BioSyent to Present at LD Micro New York Investor Conference
BioSyent (TSXV: RX) has announced its participation in the upcoming LD Micro Invitational XV Conference in New York City.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
BioSyent (TSXV: RX) has announced its participation in the upcoming LD Micro Invitational XV Conference in New York City. The company's President and CEO, René Goehrum, is scheduled to deliver an in-person presentation on Thursday, April 10th at 12:00pm EDT.
In addition to the presentation, Goehrum will be available for one-on-one meetings with investors throughout April 10th. Interested investors who are registered conference attendees can schedule these private meetings through the official LD Micro Invitational XV online conference portal.
Details
News Market Reaction – BIOYF
The recorded move for BIOYF in the trading session of this news was -3.77%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Mississauga, Ontario--(Newsfile Corp. - April 4, 2025) - BioSyent Inc. (TSXV: RX) ("BioSyent" or the "Company") announces that Mr. René Goehrum, President and CEO of BioSyent, will be presenting in person at the LD Micro Invitational XV Conference in New York City on Thursday, April 10th at 12:00pm EDT. Mr. Goehrum will also be available to meet with investors on a one-on-one basis during the conference on April 10th. These one-on-one meetings can be requested by registered attendees through the online conference portal: LD Micro Invitational XV.
About BioSyent Inc.
Listed on the TSX Venture Exchange under the trading symbol "RX", BioSyent is a profitable growth-oriented specialty pharmaceutical company focused on in-licensing or acquiring innovative pharmaceutical and other healthcare products that have been successfully developed, are safe and effective, and have a proven track record of improving the lives of patients. BioSyent supports the healthcare professionals that treat these patients by marketing its products through its community, specialty and international business units.
As of the date of this press release, the Company has 11,254,638 common shares outstanding.
For a direct market quote for the TSX Venture Exchange and other Company financial information please visit www.tmxmoney.com.
For further information please contact:
Mr. René C. Goehrum
President and CEO
BioSyent Inc.
E-Mail: investors@biosyent.com
Phone: 905-206-0013
Web: www.biosyent.com
This press release may contain information or statements that are forward-looking. The contents herein represent our judgment, as at the release date, and are subject to risks and uncertainties that may cause actual results or outcomes to be materially different from the forward-looking information or statements. Potential risks may include, but are not limited to, those associated with clinical trials, product development, future revenue, operations, profitability and obtaining regulatory approvals.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/247398
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.